



## Development of Novel Mucosal Vaccines: Advances in Technology and Delivery

Guest Editor:

**Dr. Mohamed I. Husseiny El-Sayed**

Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA

Deadline for manuscript submissions:  
**closed (31 January 2026)**

### Message from the Guest Editor

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue, where we aim to focus on pathogens that invade the body through mucosal sites. Examples of this include oral and intranasal vaccination, which have emerged as promising approaches for mucosal vaccine delivery. Technological advancements in mucosal vaccination have heightened immunological responses, simplified administration, and enhanced efficacy.

The primary objective of this Special Issue is to describe the latest technological developments that enable the effective delivery of vaccines, specifically focusing on mucosal vaccines and their development, production, processing, and design. Additionally, novel vaccine platforms for mucosal immunization, such as mRNA, DNA, viral vectors, live attenuated bacteria, bacterial vectors, and encapsulation techniques, are of interest.

We look forward to receiving your contributions.

Best regards,





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)